The short answer
In 2024 the Drug Enforcement Administration proposed moving cannabis from Schedule I to Schedule III of the Controlled Substances Act. The proposal was published in the Federal Register on May 21, 2024, and the public comment window closed on July 22, 2024. The rule was not final when the year ended. The DEA scheduled a hearing before an administrative law judge for December 2, 2024, then moved that hearing to January 21, 2025. Until a final rule is published and takes effect, cannabis remains a Schedule I substance under federal law.
latest news on cannabis rescheduling
Dates that mattered in 2024
- August 2023: the Department of Health and Human Services recommended Schedule III after an FDA review. The letter became public in January 2024.
- May 21, 2024: DEA and DOJ published the proposed rule in the Federal Register.
- July 22, 2024: the comment period closed. The docket drew tens of thousands of comments.
- Late August 2024: the DEA said the matter would go to an administrative hearing.
- November 2024: the DEA postponed the December 2 hearing to January 21, 2025.
Before you read the next headline
- Pull the original document, not a summary of a summary.
- Note the date on the document and the date on the story.
- Identify which agency spoke, because each one plays a different role.
How to read a rescheduling headline in five steps
Coverage of this topic blends recommendations, proposals, and final rules into one story. Run any article through this sequence before you act on it.
- Name the agency that spoke. HHS recommends, DEA proposes and decides, and DOJ signs off on the proposal.
- Find the words "proposed" or "final." A proposed rule changes nothing on its own.
- Check the Federal Register entry for the publication date and the current status line.
- Look for the schedule number. Schedule III is not legalization.
- Check whether the hearing date is live or has been postponed again.
What a move to Schedule III would change
- Tax treatment. The 280E limit on deductions applies to Schedule I and Schedule II substances. Schedule III placement removes that limit for state-legal operators.
- Research. Registration rules for Schedule III studies are less restrictive than the rules for Schedule I.
- Prescription channel. Schedule III drugs can be dispensed by prescription under federal law, but a cannabis product would still need FDA approval before it could be marketed that way.
What it would not change
- Recreational use stays illegal under federal law.
- State licensing, testing, labeling, and retail rules stay in place.
- Moving state-legal cannabis across state lines stays a federal offense.
- Banking and payment reform still depends on Congress.
- Local zoning, delivery boundaries, and hours of operation are untouched.
Where convenience fits
Convenience has become the deciding factor in cannabis for a large share of shoppers. Delivery windows, curbside pickup, and short in-store waits now shape which retailer keeps a customer. Nothing in the 2024 rescheduling proposal touches those state retail rules, and no hearing date changes a store's hours. What a final rule could shift over time is the money and the supply chain. Lower tax exposure gives operators room to invest in faster fulfillment and wider delivery zones. A separate prescription channel could put some products in pharmacies, which changes the trip a patient makes. Both changes would arrive late and apply to narrow product categories. Treat them as a direction, not a plan.
cannabis rescheduling impact on laws
What to do with this update
Assume Schedule I rules apply today. Keep state compliance records current, since a federal schedule change would not erase state obligations. Watch the Federal Register for a final rule, and treat any hearing delay as a delay rather than a decision. If you run a business, model the 280E change as a possible outcome and keep your current filings accurate either way.